Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Pharmaceutical Business	427.18M	426.01M	483.10M	548.95M	511.66M
Pharmaceutical Business Growth	0.27%	-11.82%	-12.00%	7.29%	9.60%
Unallocated Other Business	5.55M	3.46M	6.19M	19.26M	10.03M
Unallocated Other Business Growth	60.47%	-44.10%	-67.86%	92.00%	0.47%
Total	432.73M	429.47M	489.29M	568.21M	521.70M
Total Growth	0.76%	-12.23%	-13.89%	8.92%	9.40%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Abroad	198.43M	211.23M	307.89M	370.64M	355.71M
Abroad Growth	-6.06%	-31.39%	-16.93%	4.20%	-0.77%
China	234.30M	218.24M	181.40M	197.57M	165.98M
China Growth	7.36%	20.31%	-8.19%	19.03%	40.20%
Total	432.73M	429.47M	489.29M	568.21M	521.70M
Total Growth	0.76%	-12.23%	-13.89%	8.92%	9.40%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 15, 2026

Data Sources Report a data error